Results 21 to 30 of about 54,811 (309)
Regulatory Mechanisms in Biosystems, 2019 The activity of antioxidant protection enzymes in the blood serum and colon mucosa in rats was studied under the conditions of 28-days administration of omeprazole on its own and omeprazole together with multiprobiotics "Symbiter" and "Apibact ...
S. V. Pylypenko, A. A. Koval
doaj +1 more source
Journal of Veterinary Internal Medicine, 2023 Background Rebound gastric hyperacidity (RGH) secondary to hypergastrinemia has been suggested to contribute to the rapid recurrence of equine squamous gastric disease (ESGD) in horses after discontinuation of omeprazole.
Bethanie Clark +6 more
doaj +1 more source
Identification of new omeprazole metabolites in wastewaters and surface waters [PDF]
, 2014 Omeprazole is one of the world-wide most consumed pharmaceuticals for treatment of gastric diseases. As opposed to other frequently used pharmaceuticals, omeprazole is scarcely detected in urban wastewaters and environmental waters. This was corroborated
Boix Sales, Clara +5 more
core +1 more source
Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. [PDF]
PLoS ONE, 2013 The effect of omeprazole on the mitochondrial carnitine/acylcarnitine transporter has been studied in proteoliposomes. Externally added omeprazole inhibited the carnitine/carnitine antiport catalysed by the transporter.
Annamaria Tonazzi +2 more
doaj +1 more source
Degradation of lansoprazole and omeprazole in the aquatic environment [PDF]
, 2006 Lansoprazole and omeprazole degrade in water leading to sulfides, benzimidazolones and a red complex material. Degradation is accelerated in acid medium and by solar simulator irradiation.
BRIGANTE M. +5 more
core +1 more source
Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study [PDF]
, 2006 OBJECTIVE: In recent years, studies investigated to what extend recommendations for co-prescribing gastroprotective agents in prevention of NSAID-induced gastrointestinal complications are followed in clinical practice.
Bilušić, Marinko +6 more
core +1 more source
Frontiers in Plant Science, 2019 Omeprazole is a selective proton pump inhibitor in humans that inhibits the H+/K+-ATPase of gastric parietal cells. Omeprazole has been recently shown to act as a plant growth regulator and enhancer of salt stress tolerance.
Michael James Van Oosten +7 more
doaj +1 more source
UNDULY ENHANCED RESPONSE TO TOLVAPTAN IN A WOMAN SHOWING SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: AN INVESTIGATION OF POSSIBLE CAUSES [PDF]
, 2017 Objective: To investigate possible causes of an excessive response to tolvaptan in a woman with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Lanzellotti, Davide +4 more
core +1 more source
Drug points: Lethargy with omeprazole [PDF]
BMJ, 1997 We report a case of serious mental changes after omeprazole use in an otherwise healthy man. Rechallenge with the drug produced the same symptoms. A 64 year old former security officer presented with symptoms of reflux disease. After endoscopy he was treated with omeprazole 40 mg daily for Barrett's oesophagitis.
J P Ottervanger +4 more
openaire +3 more sources
Heliyon, 2022 Omeprazole, a proton pump inhibitor (PPI), has widely been used to treat various gastrointestinal (GI) disorders. Notably, many clinical symptoms of GI disorders have been known to be associated with anxiety.
Harini Sri Rethinavel +5 more
doaj